Abstract
AbstractProstate cancer is the second most common cancer in men and affects 1 in 9 men in the United States. Early screening for prostate cancer often involves monitoring levels of prostate-specific antigen (PSA) and performing digital rectal exams. However, a prostate biopsy is always required for definitive cancer diagnosis. The Early Detection Research Network (EDRN) is a consortium within the National Cancer Institute aimed at improving screening approaches and early detection of cancers. As part of this effort, the Weill Cornell EDRN Prostate Cancer has collected and biobanked specimens from men undergoing a prostate biopsy between 2008 and 2017. In this report, we describe blood metabolomics measurements for a subset of this population. The dataset includes detailed clinical and prospective records for 580 patients who underwent prostate biopsy, 287 of which were subsequentially diagnosed with prostate cancer, combined with profiling of 1,482 metabolites from plasma samples collected at the time of biopsy. We expect this dataset to provide a valuable resource for scientists investigating prostate cancer metabolism.
Publisher
Springer Science and Business Media LLC
Subject
Library and Information Sciences,Statistics, Probability and Uncertainty,Computer Science Applications,Education,Information Systems,Statistics and Probability
Reference27 articles.
1. Wang, L. et al. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health 10, (2022).
2. Sosnowski, R. et al. Active surveillance for low-risk prostate cancer – in pursuit of a standardized protocol. Cent. Eur. J. Urol. 73, 123–126 (2020).
3. Cancer of the Prostate - Cancer Stat Facts. SEER https://seer.cancer.gov/statfacts/html/prost.html.
4. Prensner, J. R., Rubin, M. A., Wei, J. T. & Chinnaiyan, A. M. Beyond PSA: The Next Generation of Prostate Cancer Biomarkers. Sci. Transl. Med. 4, 127rv3-127rv3 (2012).
5. Sartor, C. I. et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int. J. Radiat. Oncol. 38, 941–947 (1997).